Moderna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions.

The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start" with more than 3,500 healthcare ...

The global pediatric vaccine market is set for unprecedented growth, with a valuation of US$ 54,130.1 million in 2023, ...

Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...

The FDA previously designated the ADC as a breakthrough drug for relapsed or refractory extensive-stage small-cell lung ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.00.

(Alliance News) - GSK PLC on Tuesday said the US Food & Drug Administration has granted a breakthrough therapy designation to its treatment for a form of bone cancer.

Stocks in London are set to open lower on Tuesday, with a eurozone inflation reading, and US data in focus. Both batches of data will be scrutinised for what they could mean for the European Central ...

Pharma companies in India are expected to report healthy earnings growth in the just-concluded October-December quarter, ...